Recombinant N-terminal outer membrane porin (OprF) of Pseudomonas aeruginosa is a promising vaccine candidate against both P. aeruginosa and some strains of Acinetobacter baumannii

Bahey-El-Din, Mohammed; Mohamed, Shaymaa Abdelrahman; Sheweita, Salah A.; Haroun, Medhat A.; Zaghloul, Taha I.

doi:10.1016/j.ijmm.2020.151415

Cited by 27 publications

(17 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other approaches involving OprF and OprI include mice immunisation with the N-terminal domain of OprF, which elicited specific and protective IgG1 and IgG2 antibodies [154]. Co-administration of OMPs with other antigens was performed as early as 1993, with administration of combinations of OprF, elastase, and ETA toxoid in a rat model of chronic pulmonary infection, although combinations with elastase or ETA toxoid did not improve the protective efficacy provided by OprF alone [156].…”

Section: Oprf Major Porin and Opri Lipoproteinmentioning

confidence: 99%

“…Aluminium hydroxide (Al(OH) 3 ) and aluminium phosphate (AlPO 4 ), commonly referred to as "alum", are the most widely used adjuvants in preclinical and clinical trials of P. aeruginosa vaccines [137,154,217]. This is not surprising, given that alum was the only adjuvant approved for human vaccines until 1997, when the MF59-adjuvanted seasonal influenza vaccine was first licensed [319,320].…”

Section: Adjuvants In Vaccines Against P Aeruginosamentioning

confidence: 99%

See 1 more Smart Citation

Understanding Pseudomonas aeruginosa–Host Interactions: The Ongoing Quest for an Efficacious Vaccine

Sainz-Mejías

Jurado‐Martín

McClean

2020

Cells

View full text Add to dashboard Cite

Pseudomonas aeruginosa is a leading cause of chronic respiratory infections in people with cystic fibrosis (CF), bronchiectasis or chronic obstructive pulmonary disease (COPD), and acute infections in immunocompromised individuals. The adaptability of this opportunistic pathogen has hampered the development of antimicrobial therapies, and consequently, it remains a major threat to public health. Due to its antimicrobial resistance, vaccines represent an alternative strategy to tackle the pathogen, yet despite over 50 years of research on anti-Pseudomonas vaccines, no vaccine has been licensed. Nevertheless, there have been many advances in this field, including a better understanding of the host immune response and the biology of P. aeruginosa. Multiple antigens and adjuvants have been investigated with varying results. Although the most effective protective response remains to be established, it is clear that a polarised Th2 response is sub-optimal, and a mixed Th1/Th2 or Th1/Th17 response appears beneficial. This comprehensive review collates the current understanding of the complexities of P. aeruginosa-host interactions and its implication in vaccine design, with a view to understanding the current state of Pseudomonal vaccine development and the direction of future efforts. It highlights the importance of the incorporation of appropriate adjuvants to the protective antigen to yield optimal protection.

show abstract

Section: Oprf Major Porin and Opri Lipoproteinmentioning

confidence: 99%

Section: Adjuvants In Vaccines Against P Aeruginosamentioning

confidence: 99%

Understanding Pseudomonas aeruginosa–Host Interactions: The Ongoing Quest for an Efficacious Vaccine

Sainz-Mejías

Jurado‐Martín

McClean

2020

Cells

View full text Add to dashboard Cite

show abstract

“…Mice were thus at the best immunized against linear epitopes belonging to OprF 25-200 . The authors reported that mice immunization with OprF 25-200 conferred a maximum protection rate of 50%, 48 h after a challenge with Acinetobacter baumannii, a clinical isolate expressing OprF (Bahey-El-Din et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

Cell-free expression of the outer membrane protein OprF of Pseudomonas aeruginosa for vaccine purposes

et al. 2021

View full text Add to dashboard Cite

Pseudomonas aeruginosa is the second-leading cause of nosocomial infections and pneumonia in hospitals. Because of its extraordinary capacity for developing resistance to antibiotics, treating infections by Pseudomonas is becoming a challenge, lengthening hospital stays, and increasing medical costs and mortality. The outer membrane protein OprF is a well-conserved and immunogenic porin playing an important role in quorum sensing and in biofilm formation. Here, we used a bacterial cell-free expression system to reconstitute OprF under its native forms in liposomes and we demonstrated that the resulting OprF proteoliposomes can be used as a fully functional recombinant vaccine against P. aeruginosa. Remarkably, we showed that our system promotes the folding of OprF into its active open oligomerized state as well as the formation of mega-pores. Our approach thus represents an easy and efficient way for producing bacterial membrane antigens exposing native epitopes for vaccine purposes.

show abstract

“…Over the past two decades, there have been less than a dozen studies of prophylactic vaccines tested against Pa BSI or sepsis in animal models ( Table 1 ). Nonetheless, several candidate antigens including secreted proteins ( Farajnia et al, 2015 ; Wang et al, 2018 ; Yang et al, 2018 ), surface and outer membrane components ( Yu et al, 2016 ; Ryu et al, 2017 ; Elhosary et al, 2019 ; Bahey-El-Din et al, 2020 ), and other virulence factors ( Kao et al, 2007 ; Moriyama et al, 2009 ; Aguilera-Herce et al, 2019 ; Elhosary et al, 2019 ; Afshari et al, 2021 ) combined with different delivery methods and adjuvants have shown promising results.…”

Section: Introductionmentioning

confidence: 99%

“…The potential of the under-investigated N-terminal porin domain of OprF as a stand-alone recombinant protein vaccine was also investigated against Pa ( Bahey-El-Din et al, 2020 ). Immunization with N-terminal OprF elicited antigen-specific IgG1 and IgG2a and significantly reduced bacterial burdens in the kidney and lung tissues of vaccinated mice as compared to the controls ( Bahey-El-Din et al, 2020 ). Immunization with N-terminal OprF also significantly reduced liver pathology at 48 h post i.p challenge with Pa ( Bahey-El-Din et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Vaccination to Prevent Pseudomonas aeruginosa Bloodstream Infections

Hart

Morici

2022

Front. Microbiol.

View full text Add to dashboard Cite

The bacterium Pseudomonas aeruginosa (Pa) is ubiquitous in the environment and causes opportunistic infections in humans. Pa is increasingly becoming one of the most difficult to treat microorganisms due to its intrinsic and acquired resistance to multiple antibiotics. The World Health Organization estimates that at least 700,000 people die each year from drug resistant microbial infections and have listed Pa as one of three bacterial species for which there is the most critical need for the development of novel therapeutics. Pa is a common cause of bloodstream infections (BSI) and bacterial sepsis. With nearly 49 million sepsis cases and 11 million deaths worldwide, an effective vaccine against Pa could prevent the morbidity and mortality resulting from Pa BSI and lessen our dependence on antibiotics. We reviewed the current landscape of Pa vaccines in pre-clinical and clinical stages over the last two decades. It is readily apparent that Pa vaccine development efforts have been largely directed at the prevention of pulmonary infections, likely due to Pa’s devastating impact on individuals with cystic fibrosis. However, the increase in nosocomial infections, BSI-related sepsis, and the emergence of widespread antibiotic resistance have converged as a major threat to global public health. In this perspective, we draw attention to potential Pa vaccine candidates and encourage a renewed effort for prophylactic vaccine development to prevent drug-resistant Pa BSI.

show abstract

Recombinant N-terminal outer membrane porin (OprF) of Pseudomonas aeruginosa is a promising vaccine candidate against both P. aeruginosa and some strains of Acinetobacter baumannii

Cited by 27 publications

References 40 publications

Understanding Pseudomonas aeruginosa–Host Interactions: The Ongoing Quest for an Efficacious Vaccine

Understanding Pseudomonas aeruginosa–Host Interactions: The Ongoing Quest for an Efficacious Vaccine

Cell-free expression of the outer membrane protein OprF of Pseudomonas aeruginosa for vaccine purposes

Vaccination to Prevent Pseudomonas aeruginosa Bloodstream Infections

Contact Info

Product

Resources

About